The effecs of intensive lipid-lowering therapy on the progression of atherosclerotic kidney disease

The effecs of intensive lipid-lowering therapy on the progression of atherosclerotic kidney disease - Lipid-lowering therapy for CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021356

Enrollment

40

Registered

2016-03-31

Start date

2011-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

5mg of robuvastatin

Sponsors

University, School of Medicine

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Normotensive patients with chronic kidney disease

Exclusion criteria

Exclusion criteria: patients with diabetes

Design outcomes

Primary

Measure	Time frame
Parameters of the ultrasound doppler technique	—

Countries

Japan

Contacts

Public ContactShu Wakino

Keio University, School of Medicine Division of Nephrology, Endocrinology, and Diabetes

shuwakino@z8.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026